CN113573734A - 治疗癌症的方法 - Google Patents

治疗癌症的方法 Download PDF

Info

Publication number
CN113573734A
CN113573734A CN201980089704.1A CN201980089704A CN113573734A CN 113573734 A CN113573734 A CN 113573734A CN 201980089704 A CN201980089704 A CN 201980089704A CN 113573734 A CN113573734 A CN 113573734A
Authority
CN
China
Prior art keywords
cancer
brm
brg1
optionally substituted
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980089704.1A
Other languages
English (en)
Chinese (zh)
Inventor
R·C·森托雷
L·许
D·拉尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuhong Treatment Co
Original Assignee
Fuhong Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuhong Treatment Co filed Critical Fuhong Treatment Co
Publication of CN113573734A publication Critical patent/CN113573734A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980089704.1A 2018-11-21 2019-11-21 治疗癌症的方法 Pending CN113573734A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862770446P 2018-11-21 2018-11-21
US62/770446 2018-11-21
US201962798238P 2019-01-29 2019-01-29
US62/798238 2019-01-29
US201962858036P 2019-06-06 2019-06-06
US62/858036 2019-06-06
PCT/US2019/062525 WO2020106915A1 (en) 2018-11-21 2019-11-21 Methods of treating cancers

Publications (1)

Publication Number Publication Date
CN113573734A true CN113573734A (zh) 2021-10-29

Family

ID=70774067

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980089704.1A Pending CN113573734A (zh) 2018-11-21 2019-11-21 治疗癌症的方法

Country Status (5)

Country Link
US (2) US20220016083A1 (https=)
EP (1) EP3883580A4 (https=)
JP (1) JP2022508155A (https=)
CN (1) CN113573734A (https=)
WO (1) WO2020106915A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115484948A (zh) * 2020-01-29 2022-12-16 福宏治疗公司 化合物及其用途

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087885A1 (en) 2015-11-19 2017-05-26 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
US11497752B2 (en) 2018-01-30 2022-11-15 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
EP3917517A4 (en) 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
CN113645971B (zh) * 2019-01-29 2024-10-18 福宏治疗公司 化合物及其用途
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
AU2021213811A1 (en) 2020-01-29 2022-07-28 Foghorn Therapeutics Inc. Compounds and uses thereof
TW202146412A (zh) 2020-03-05 2021-12-16 美商Ｃ４醫藥公司 用於標靶降解brd9之化合物
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
AU2021293943A1 (en) * 2020-06-18 2023-02-23 Epizyme, Inc. SMARCA4 inhibition for the treatment of cancer
KR20230128471A (ko) * 2020-12-04 2023-09-05 에우불루스 바이오테라퓨틱스 인코포레이티드 헤테로아릴-아세틸렌, 이의 약제학적 조성물, 및 이의치료적 적용
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
US20240374605A1 (en) * 2021-07-29 2024-11-14 Foghorn Therapeutics Inc. Methods of treating cancer
US20230265432A1 (en) * 2021-10-21 2023-08-24 Sanford Burnham Prebys Medical Discovery Institute Methods and compositions for treating acute myeloid leukemia
WO2023234954A1 (en) * 2022-06-03 2023-12-07 Immunocore Limited Methods of treating melanoma using tebentafusp and immune checkpoint inhibitors
EP4587126A1 (en) 2022-09-13 2025-07-23 Amphista Therapeutics Ltd Compounds for targeted protein degradation
WO2024086577A1 (en) * 2022-10-17 2024-04-25 Foghorn Therapeutics Inc. Methods of reducing or preventing metastases
WO2026052822A1 (en) 2024-09-06 2026-03-12 Amphista Therapeutics Limited Tetrahydroisoquinoline compounds for targeted protein degradation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160032402A1 (en) * 2013-03-15 2016-02-04 Novartis Ag Biomarkers associated with brm inhibition
US20160130663A1 (en) * 2013-07-12 2016-05-12 National Cancer Center Method for predicting response to cancer treatment
US20160176916A1 (en) * 2014-12-23 2016-06-23 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US20180086720A1 (en) * 2015-02-25 2018-03-29 Genentech, Inc. Therapeutic compounds and uses thereof
WO2018160636A1 (en) * 2017-02-28 2018-09-07 Epizyme, Inc. Inhibition of smarca2 for treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017024318A1 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
AU2018219292B2 (en) * 2017-02-08 2024-09-26 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160032402A1 (en) * 2013-03-15 2016-02-04 Novartis Ag Biomarkers associated with brm inhibition
US20160130663A1 (en) * 2013-07-12 2016-05-12 National Cancer Center Method for predicting response to cancer treatment
US20160176916A1 (en) * 2014-12-23 2016-06-23 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US20180086720A1 (en) * 2015-02-25 2018-03-29 Genentech, Inc. Therapeutic compounds and uses thereof
WO2018160636A1 (en) * 2017-02-28 2018-09-07 Epizyme, Inc. Inhibition of smarca2 for treatment of cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115484948A (zh) * 2020-01-29 2022-12-16 福宏治疗公司 化合物及其用途

Also Published As

Publication number Publication date
EP3883580A1 (en) 2021-09-29
US20220016083A1 (en) 2022-01-20
JP2022508155A (ja) 2022-01-19
WO2020106915A1 (en) 2020-05-28
EP3883580A4 (en) 2023-01-04
US20250235432A1 (en) 2025-07-24

Similar Documents

Publication Publication Date Title
CN113573734A (zh) 治疗癌症的方法
US12383555B2 (en) Methods of treating cancers
CN115867314A (zh) 治疗癌症的方法
US20240150328A1 (en) Methods and compounds for treating disorders
US20210251988A1 (en) Methods of treating disorders
CN116745288B (zh) 化合物及其用途
US20210260171A1 (en) Methods of treating disorders
US12552775B2 (en) Compounds and uses thereof
US20240374605A1 (en) Methods of treating cancer
TW202136252A (zh) 化合物及其用途
US11787800B2 (en) BRD9 degraders and uses thereof
CN119343142A (zh) 治疗具有与血细胞分化相关的临床显著体征和症状的受试者的方法
WO2024086577A1 (en) Methods of reducing or preventing metastases
Winter et al. Antitumoral activity of a trichloromethyl pyrimidine analogue: molecular cross-talk between intrinsic and extrinsic apoptosis
WO2025015149A2 (en) Methods of treating cancer
CN113543789A (zh) 用于癌症治疗的脱氧胞苷或尿苷衍生物
CA2923765C (en) Stem cell modulation ii
CN107074791A (zh) 用于抑制hsp27的胸腺嘧啶衍生物和喹唑啉二酮衍生物
WO2019036417A2 (en) INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER
CN118043053A (zh) 治疗癌症的方法
HK40090754A (zh) 治疗癌症的方法
WO2022025880A1 (en) Compounds and uses thereof
CN121100116A (zh) 化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211029

WD01 Invention patent application deemed withdrawn after publication